Sangamo Therapeutics (SGMO)

P/S ratio as of September 2024 (TTM): 14.2

According to Sangamo Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.1974. At the end of 2024 the company had a P/S ratio of 6.06.

P/S ratio history for Sangamo Therapeutics from 2001 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	6.06	1007.68%
2023	0.5467	-88.17%
2022	4.62	-53.15%
2021	9.87	-47.15%
2020	18.7	97.06%
2019	9.48	-31.78%
2018	13.9	-63.36%
2017	37.9	241.21%
2016	11.1	-31.62%
2015	16.2	-29.06%
2014	22.9	-36.08%
2013	35.8	143.29%
2012	14.7	1.97%
2011	14.4	-0.28%
2010	14.5	20.63%
2009	12.0	36.26%
2008	8.81	-84.73%
2007	57.7	96.7%
2006	29.3	-40.88%
2005	49.6	-56.97%
2004	115	117.86%
2003	52.9	208.67%
2002	17.1	-63.37%
2001	46.8

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Gilead Sciences GILD	3.76	-73.54%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	15.0	5.36%	🇺🇸 USA
Amgen AMGN	5.78	-59.27%	🇺🇸 USA
Biogen BIIB	2.98	-79.04%	🇺🇸 USA
Dow DOW	0.8412	-94.08%	🇺🇸 USA
Johnson & Johnson JNJ	4.62	-67.46%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	5.23	-63.14%	🇺🇸 USA
Merck MRK	4.81	-66.10%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is receiving financial compensation for Delta App installs.
CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Sangamo Therapeutics (SGMO)

P/S ratio as of September 2024 (TTM): 14.2